Ultime notizie per Ventyx Biosciences (NASDAQ:VTYX) Azioni

Ventyx Biosciences

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Ventyx Biosciences Inc

The following tables summarize the fiscal year 2025 guidance framework and does not include any impact from the proposed portfolio transactions announced today. The 2025 outlook assumes approximately $1.2 billion of dividend payments. Guidance figures are approximate.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2025 Q1</td>
<td colspan="1" rowspan="1">2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Sales Growth</td>
<td colspan="1" rowspan="1">2.5% - 3.5%</td>
<td colspan="1" rowspan="1">3.5% - 5.5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Underlying Sales Growth</td>
<td colspan="1" rowspan="1">2% - 3%</td>
<td colspan="1" rowspan="1">3% - 5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Earnings Per Share</td>
<td colspan="1" rowspan="1">$0.89 - $0.94</td>
<td colspan="1" rowspan="1">$4.42 - $4.62</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of Intangibles</td>
<td colspan="1" rowspan="1">~$0.31</td>
<td colspan="1" rowspan="1">~$1.23</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Restructuring / Related Costs</td>
<td colspan="1" rowspan="1">~$0.04</td>
<td colspan="1" rowspan="1">~$0.16</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Acquisition / Divestiture Fees and Related Costs</td>
<td colspan="1" rowspan="1">~$0.01</td>
<td colspan="1" rowspan="1">~$0.04</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Earnings Per Share</td>
<td colspan="1" rowspan="1">$1.25 - $1.30</td>
<td colspan="1" rowspan="1">$5.85 - $6.05</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Cash Flow</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$3.6B - $3.7B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$3.2B - $3.3B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Share Repurchase</td>
<td colspan="1" rowspan="1">~$1.0B</td>
<td colspan="1" rowspan="1">~$2.0B</td>
</tr>
</tbody>
</table>
</figure>

Earnings

News

Guidance

Emerson Provides  2025 Outlook: Sees Net Sales Growth Of 3.5% - 5.5%; Adj. EPS Of $5.85 - $6.05 Vs. $5.48 Est.

Keybanc analyst Alex Markgraff downgrades Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) from Overweight to Sector Weight.

Downgrades

Analyst Ratings

Keybanc Downgrades Marqeta to Sector Weight

WIIM

Archer Daniels Midland shares are trading lower after the company released preliminary Q3 results below estimates and lowered its FY24 adjusted EPS guidance.

B of A Securities analyst Travis Steed initiates coverage on CeriBell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) with a Buy rating and announces Price Target of $32.

Price Target

Initiation

CBLL

B of A Securities Initiates Coverage On CeriBell with Buy Rating, Announces Price Target of $32

Stevanato Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) lowers FY2024 Adj EPS guidance from $0.52-0.54 to $0.52-0.54 vs $0.49 analyst estimate. Raises FY2024 sales outlook from $1.17 billion-1.20 billion to $1.20 billion-1.22 billion vs $1.09 billion estimate.

STVN

Stevanato Group expects FY 2024 revenue to remain between €1,090 million and €1,110 million ;lowering adjusted EBITDA to €257 million - €263 million and adjusted diluted EPS to €0.47 - €0.49.

Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) reported quarterly earnings of $1.87 per share which beat the analyst consensus estimate of $0.98 by 90.82 percent. This is a 77.03 percent decrease over earnings of $8.14 per share from the same period last year. The company reported quarterly sales of $35.373 billion which beat the analyst consensus estimate of $32.835 billion by 7.73 percent. This is a 14.93 percent decrease over sales of $41.583 billion the same period last year.

Earnings Beats

Marathon Petroleum Q3 2024 Adj. EPS $1.87 Beats $0.98 Estimate, Sales $35.373B Beat $32.835B Estimate

Nomura Holdings shares are trading higher after the company reported Q2 financial results.

The Q3 earnings report for Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) was released on Thursday, October 24, 2024 at 04:05 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Boyd Gaming beat estimated earnings by 10.0%, reporting an EPS of $1.52 versus an estimate of $1.38.
Revenue was up $58.08 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.09 in the previous quarter, leading to a 4.0% increase share price change the next day.
Here's a look at Boyd Gaming's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.38</td>
<td>1.49</td>
<td>1.57</td>
<td>1.47</td>
<td>1.47</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.52</td>
<td>1.58</td>
<td>1.51</td>
<td>1.66</td>
<td>1.36</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>912.95M</td>
<td>909.06M</td>
<td>958.74M</td>
<td>930.47M</td>
<td>879.82M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>961.25M</td>
<td>967.51M</td>
<td>960.52M</td>
<td>954.41M</td>
<td>903.16M</td>
</tr>
</tbody>
</table>

<h3>Comparison of Competitors' Recent Earnings</h3>
As we analyze Boyd Gaming's earnings, it's important to contextualize its numbers by examining how it fares against its industry rivals, such as PENN Entertainment, Golden Entertainment, and Inspired Entertainment.
<ul>
<li>PENN Entertainment's earnings announcement on August 08, 2024 exceeded expectations, with an actual EPS of $-0.18 compared to the market's projected EPS of $-0.26, resulting in a 30.77% increase.</li>
<li>Despite market projections of an EPS of $0.21, Golden Entertainment's earnings on August 08, 2024 fell short with an actual EPS of $0.02, representing a -90.48% decrease from expectations.</li>
<li>The latest earnings announcement from Inspired Entertainment on August 08, 2024 exceeded expectations, with an actual EPS of $0.2 compared to the market's estimate of $0.1, resulting in a 100.0% increase.</li>
</ul>
<h3>Quarterly Analysis: Competitors' Earnings and Stock Performance</h3>
Insights into the market's response to the latest earnings releases of key competitors are provided in this analysis. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Date</th>
<th style="text-align: right;">EPS Expected</th>
<th style="text-align: right;">EPS Announced</th>
<th>EPS Change Percent</th>
<th>Stock Price At Close</th>
<th>Stock Price at Next Day Open</th>
<th>Price Change Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyd Gaming</td>
<td>October 24, 2024</td>
<td style="text-align: right;">1.38</td>
<td style="text-align: right;">1.52</td>
<td>10.14%</td>
<td>$64.31</td>
<td>$69.96</td>
<td>8.79%</td>
</tr>
<tr>
<td>PENN Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.26</td>
<td style="text-align: right;">-0.18</td>
<td>30.77%</td>
<td>$18.72</td>
<td>$18.83</td>
<td>0.59%</td>
</tr>
<tr>
<td>Golden Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.21</td>
<td style="text-align: right;">0.02</td>
<td>-90.48%</td>
<td>$28.12</td>
<td>$27.42</td>
<td>-2.49%</td>
</tr>
<tr>
<td>Inspired Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.10</td>
<td style="text-align: right;">0.20</td>
<td>100.0%</td>
<td>$8.48</td>
<td>$8.39</td>
<td>-1.06%</td>
</tr>
</tbody>
</table>

<h3>Analyzing Peer Revenue Discrepancy: Estimated vs. Announced</h3>
The following table compares estimated and announced revenue figures for Boyd Gaming's peers. This comparison provides insights into the revenue performance of these companies, offering valuable context to understand their financial standing within the industry.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Estimated Revenue</th>
<th>Announced Revenue</th>
<th>Revenue Surprise Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyd Gaming</td>
<td>912.95M</td>
<td>961.25M</td>
<td>5.29%</td>
</tr>
<tr>
<td>PENN Entertainment</td>
<td>1.66B</td>
<td>1.66B</td>
<td>0.18%</td>
</tr>
<tr>
<td>Golden Entertainment</td>
<td>174.60M</td>
<td>167.33M</td>
<td>-4.16%</td>
</tr>
<tr>
<td>Inspired Entertainment</td>
<td>74.41M</td>
<td>75.60M</td>
<td>1.6%</td>
</tr>
</tbody>
</table>

To track all earnings releases for Boyd Gaming <a href="https://www.benzinga.com/quote/BYD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Boyd Gaming Q3 Earnings

Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) reported quarterly earnings of $1.85 per share which beat the analyst consensus estimate of $1.72 by 7.56 percent. The company reported quarterly sales of $7.773 billion which beat the analyst consensus estimate of $4.131 billion by 88.18 percent. This is a 199.54 percent increase over sales of $2.595 billion the same period last year.

Apollo Global Management Q3 2024 Adj. EPS $1.85 Beats $1.72 Estimate, Sales $7.773B Beat $4.131B Estimate

ALAB

Astera Labs shares are trading higher after the company reported better-than-expected Q3 EPS and sales.

MRUS

Merus Says FDA Extended PDUFA Goal Date For Zenocutuzumab Biologics License Application Currently Under Priority Review To February 4, 2025

JMP Securities analyst Reni Benjamin downgrades Sana Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) from Market Outperform to Market Perform.

SANA

JMP Securities Downgrades Sana Biotechnology to Market Perform

Stevanato Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.14 by 7.14 percent. This is a 18.75 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $305.44 million which beat the analyst consensus estimate of $298.33 million by 2.38 percent. This is a 3.40 percent increase over sales of $295.41 million the same period last year.

Earnings Misses

Stevanato Gr Q3 Adj $0.13 Misses $0.14 Estimate, Sales $305.44M Beat $298.33M Estimate

Easterly Government Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.29 by 3.45 percent. This is a 3.45 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $74.781 million which missed the analyst consensus estimate of $76.703 million by 2.51 percent. This is a 3.84 percent increase over sales of $72.014 million the same period last year.

Easterly Government Props Q3 2024 FFO $0.30 Beats $0.29 Estimate, Sales $74.781M Miss $76.703M Estimate

U.S. stocks could open on a tentative note on Tuesday after the <a href="https://www.benzinga.com/news/earnings/24/11/41696201/market-volatility-soars-ahead-of-elections-tech-earnings-mixed-strikes-and-hurricanes-knock-employm">averages registered a mixed October</a>. Futures of all three major indices were slightly up on Tuesday, pointing to a cautious sentiment on Wall Street.
While the S&amp;P 500 and Dow Jones snapped their six-week winning streak, the Nasdaq Composite chalked its seventh straight week of gains to round off a volatile October.
America goes to polls on Tuesday to elect its 47th president, and data so far suggests that it will be a neck-to-neck race between Democratic candidate&nbsp;Kamala Harris&nbsp;and Republican nominee&nbsp;Donald Trump.
Another factor playing on investors' minds will be the Federal Open Market Committee's (FOMC) rate decision – the prevailing sentiment is that the Fed will deliver a 25-basis point cut.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.27%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.16%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.12%</td>
</tr>
<tr>
<td>R2K</td>
<td>0.05%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Tuesday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.16% to $570.71 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged up by 0.25% to $487.24, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
The Dow Jones tumbled over 250 points on Monday, closing the day down by 0.61%. The other two averages also declined amid declining investor sentiment and rising fear in the market.
Oil prices continued to rebound after tanking the week before, amid delays in production output increase by the Organization of the Petroleum Exporting Countries, or OPEC.
Treasury yields continued to rise, signaling concerns that regardless of who wins the elections, the next administration might struggle with fiscal discipline. This sentiment was further exacerbated by the International Monetary Fund's warnings on the long-term trajectory <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41495286/deficit-strain-in-washington-will-get-worse-imf-warns-national-debt-projections-rev" target="_blank" rel="noreferrer noopener">of the U.S. national debt</a>.
On the economic data front, U.S. factory orders declined by 0.5% from the previous month to $584.2 billion in September compared to a revised 0.8% fall in August.
Most sectors on the S&amp;P 500 closed on a negative note, with utilities, communication services, and financials stocks recording the biggest losses on Monday.
However, energy and real estate stocks bucked the overall market trend, closing the session higher.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.33%</td>
<td>18,179.98</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.28%</td>
<td>5,712.62</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.61%</td>
<td>41,794.60</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.40%</td>
<td>2,219.03</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Ryan Detrick, chief market strategist at Carson Group, underscored that stocks perform well on election day, which could assuage investor concerns amid rising volatility.
"What really stands out is how well stocks have done after the 10 most recent elections. Higher a year later 9 times and up 15.2% on avg (median of 17.2%)," he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Here&#39;s how stocks have done after the past 24 elections. What really stands out is how well stocks have done after the 10 most recent elections. Higher a year later 9 times and up 15.2% on avg (median of 17.2%). <a href="https://t.co/ztim9o3RxP">pic.twitter.com/ztim9o3RxP</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1853476226741989530?ref_src=twsrc%5Etfw">November 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Echoing Detrick's sentiment, WisdomTree and Wharton School economist&nbsp;Jeremy Siegel said the equity bull run could continue.
"In the near term, stock markets seem poised for further gains, bolstered by resilient earnings and steady economic fundamentals, while bond markets will likely grapple with higher yields and volatility ahead," he said.
"The bull market in stocks looks set to continue, while bonds face a rougher road."
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
Tuesday's economic calendar is fairly light.
<ul>
<li>On Tuesday, U.S. trade deficit data will be released at 8:30 a.m. ET.</li>
<li>ISM services data will be released at 10 a.m. ET.</li>
<li>API weekly crude oil stock data will be released at 4:30 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares soared 5.6% on election eve.</li>
<li>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares surged 13% in premarket trading after the company delivered strong performance and raised guidance.</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares rose nearly 2% after striking machinists ratified a new deal late Monday, ending a seven-week-long strike.</li>
<li>NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) stock fell over 5% after the company's soft guidance, despite beating expectations in the September quarter.</li>
<li>Investors are awaiting earnings results from Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>), Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) and Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures surged in the early New York session, rising by 0.4% after OPEC announced a delay in increasing production.
The 10-year Treasury note yield surged to 4.311%.
Major Asian markets ended in the green on Tuesday, and European stocks showed strength as well in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41736062/boeing-workers-end-seven-week-strike-by-accepting-new-contract-with-major-pay-increases">Boeing Workers End Seven-Week Strike By Accepting New Contract With Major Pay Increases</a></li>
</ul>
Photo courtesy: Wikimedia

Equities

Futures

Economics

Federal Reserve

Pre-Market Outlook

Markets

Movers

Trading Ideas

NXPI

PLTR

US Stocks Set For Cautious Start As Investors Brace For Volatility On Election Day: Expert Points To 'Pretty Well Overall' Historical Performance

WYNN

Wynn Resorts shares are trading lower after the company reported worse-than-expected Q3 EPS and revenues.

AZPN

Emerson Proposes To Acquire Remaining Outstanding Shares Of AspenTech For $240 Per Share In Cash

Fiscal 2025 Guidance
Certain statements in this release, including without limitation, those in this section, are forward-looking statements. For additional information regarding the use and limitations of such statements, refer to "Cautionary Note Regarding Forward-Looking Statements" below.
Based on results for the first quarter of fiscal 2025 and its current outlook for the remainder of the fiscal year, the company is reaffirming the following:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Guidance Metric</td>
<td colspan="1" rowspan="1">Fiscal 2025 Guidance Range [1] [2] (as of November 5, 2024)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Segment Net Revenue:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Supply Chain Services</td>
<td colspan="1" rowspan="1">$560 million to $610 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Performance Services Excluding Contigo Health</td>
<td colspan="1" rowspan="1">$370 million to $410 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Net Revenue Excluding Contigo Health</td>
<td colspan="1" rowspan="1">$930 million to $1.02 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$235 million to $255 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">$1.16 to $1.28</td>
</tr>
<tr>
<td colspan="2" rowspan="1">
Fiscal 2025 guidance is based on the realization of the following key assumptions:
<ul>
<li>Net administrative fees revenue of $495 million to $525 million, which includes $60 million to $75 million in revenue related to non-healthcare member purchasing</li>
<li>Supply Chain Services segment software licenses, other services and support revenue of $65 million to $85 million</li>
<li>Capital expenditures of $90 million to $100 million</li>
<li>Effective income tax rate in the range of 25% to 27%</li>
<li>Cash income tax rate of less than 5%</li>
<li>Free cash flow of 45% to 55% of adjusted EBITDA</li>
</ul>
</td>
</tr>
</tbody>
</table>
</figure>

PINC

Premier Expects FY25 Net Revenue Of $930M-$1.02B Vs $977.19M Est, Adj EPS Of $1.16-$1.28 Vs $1.21 Est

Emerson Commences Review Of Strategic Options For Safety & Productivity Segment

JMP Securities analyst Jordan Bender upgrades Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) from Market Perform to Market Outperform and announces $5 price target.

Upgrades

CNTY

JMP Securities Upgrades Century Casinos to Market Outperform, Announces $5 Price Target

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ventyx Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtyx-stock-quote/">VTYX</a>) just reported results for the second quarter of 2024.<ul><li>Ventyx Biosciences reported earnings per share of -45 cents. This was above the analyst estimate for EPS of -57 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vtyx-stock-earnings-ventyx-biosciences-for-q2-of-2024/">VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q2 2024

Ventyx Biosciences CFO departs

Ventyx Biosciences (VTYX) has issued an announcement. Ventyx Biosciences, Inc. has appointed Roy M. Gonzales as the interim principal financial off...

Ventyx Biosciences Announces Executive Financial Officer Changes

Ventyx stock climbs 8% on $27M Sanofi investment

H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target of $6.00....

Ventyx Biosciences: Cautious Optimism Amidst Sanofi's Strategic Investment and Upcoming Clinical Trials

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report). The compan...

LifeSci Capital Remains a Buy on Ventyx Biosciences (VTYX)

Oppenheimer analyst Jeff Jones maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target of $10.00. The c...

Oppenheimer Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)

Analyst Emily Bodnar from H.C. Wainwright maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) and keeping the price target at $...

Ventyx Biosciences' Tamuzimod: Promising Data but Insufficient for Upgrade Beyond Hold

In his iconic song The Gambler, Kenny Rogers famously sang, "Every hand's a winner, and every hand's a loser." This line offers valuable wisdom for...

These 2 'Strong Buy' Penny Stocks Could Rally Over 500%, Say Analysts

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

AMLX

INGN

NRGV

RGLS

VTYX

Legal

Press Releases

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

VENTYX INVESTOR ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details

VENTYX STOCK ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details

Health Care

General

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn's Disease

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Management

Ventyx Biosciences Announces Departure of Chief Financial Officer

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Financing

Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

Comments

Ventyx Biosciences

Notizie

Ultime notizie per Ventyx Biosciences (NASDAQ:VTYX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO